Invivyd's (IVVD) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Invivyd (NASDAQ:IVVD - Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Invivyd's Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.64) EPS and FY2029 earnings at $0.41 EPS.

IVVD has been the topic of several other reports. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a "strong-buy" rating in a report on Wednesday, October 30th. D. Boral Capital reissued a "buy" rating and set a $9.00 target price on shares of Invivyd in a research report on Monday. Finally, Morgan Stanley reduced their target price on Invivyd from $9.50 to $3.55 and set an "overweight" rating for the company in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Invivyd has a consensus rating of "Buy" and an average target price of $7.89.

Invivyd Stock Up 3.0 %

NASDAQ:IVVD traded up $0.06 during trading hours on Tuesday, hitting $2.04. 27,285,427 shares of the company traded hands, compared to its average volume of 30,464,357. The company has a market cap of $244.02 million, a PE ratio of -1.04 and a beta of 0.61. The firm's 50-day simple moving average is $0.58 and its 200-day simple moving average is $0.84. Invivyd has a one year low of $0.35 and a one year high of $5.10.

Insider Buying and Selling at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 150,000 shares of the business's stock in a transaction on Monday, December 9th. The stock was sold at an average price of $0.61, for a total value of $91,500.00. Following the sale, the director now directly owns 4,538,079 shares in the company, valued at $2,768,228.19. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 816,466 shares of company stock worth $423,214 over the last three months. 17.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Invivyd

Large investors have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC purchased a new position in shares of Invivyd in the third quarter worth about $27,000. Barclays PLC boosted its holdings in Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company's stock worth $120,000 after buying an additional 75,780 shares during the period. Cubist Systematic Strategies LLC grew its stake in Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company's stock valued at $148,000 after buying an additional 53,499 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Invivyd during the 2nd quarter valued at $421,000. Finally, Marshall Wace LLP lifted its position in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock worth $866,000 after acquiring an additional 31,992 shares in the last quarter. Hedge funds and other institutional investors own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.